# EMPRA (EMPagliflozin and RAs in Kidney Disease)

> **NCT03078101** · PHASE2 · COMPLETED · sponsor: **Medical University of Vienna** · enrollment: 51 (actual)

## Conditions studied

- Diabetic Kidney Disease
- Diabetes Mellitus, Type 2
- Chronic Kidney Disease stage3
- Chronic Kidney Disease stage4

## Interventions

- **DRUG:** Empagliflozin 10 MG [Jardiance]
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03078101
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-15
- **Primary completion:** 2019-06-18
- **Final completion:** 2019-08-07
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2019-08-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03078101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03078101, "EMPRA (EMPagliflozin and RAs in Kidney Disease)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03078101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*